Drug Trial Radar · NCT07093580
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Jul 29, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Conditions
- Healthy Participants
Interventions
S-892216-LAIDrug
S-892216-LAI injection will be administered per schedule specified in the arm description.
PlaceboDrug
Physiological saline will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through Day 364
- Part 2: Number of Participants With TEAEsTime frame: Day 1 through Day 448
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Altasciences
Cypress, California · Recruiting
ICON Clinical Research: Lenexa
Lenexa, Kansas · Active not recruiting
ICON Clinical Research: Salt Lake City
Salt Lake City, Utah · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.